MedPath

Dibenzyline

Rx Only                Prescribing Information Dibenzyline (phenoxybenzamine hydrochloride capsules, USP) 10 mg  adrenergic, -receptor-blocking agent

Approved
Approval ID

8852dd44-098c-4d99-88e0-a092a8e08e11

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 3, 2023

Manufacturers
FDA

Concordia Pharmaceuticals Inc.

DUNS: 815240092

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Phenoxybenzamine Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59212-001
Application NumberNDA008708
Product Classification
M
Marketing Category
C73594
G
Generic Name
Phenoxybenzamine Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateApril 14, 2020
FDA Product Classification

INGREDIENTS (6)

GELATINInactive
Code: 2G86QN327L
Classification: IACT
PHENOXYBENZAMINE HYDROCHLORIDEActive
Quantity: 10 mg in 1 1
Code: X1IEG24OHL
Classification: ACTIB
D&C RED NO. 33Inactive
Code: 9DBA0SBB0L
Classification: IACT
FD&C RED NO. 3Inactive
Code: PN2ZH5LOQY
Classification: IACT
FD&C YELLOW NO. 6Inactive
Code: H77VEI93A8
Classification: IACT
LACTOSEInactive
Code: J2B2A4N98G
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dibenzyline - FDA Drug Approval Details